Therefore, future large‐scale prospective studies are needed to investigate the dynamic changes in SII during AD progression and treatment, particularly its interactions with emerging biomarkers (e.g., IgE and IL‐13), thereby refining personalized treatment algorithms. This evidence concerns the gene IL13 and Alzheimer disease.